The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2022 | Real-world outcomes of patients with HCC treated with lenvatinib vs. atezolizumab plus bevacizumab
Mara Persano, MD, University Of Cagliari, Cagliari, Italy, discusses a real-world study comparing first-line lenvatinib vs. atezolizumab plus bevacizumab for patients with hepatocellular carcinoma (HCC). More than 2000 patients across Italy, Germany, Republic of Korea, and Japan were involved in the study; 1300 received lenvatinib and 800 received atezolizumab plus bevacizumab. The primary endpoint of the study was objective response rate (ORR), with overall survival (OS) being a secondary endpoint. The lenvatinib cohort achieved a higher ORR compared to those receiving atezolizumab plus bevacizumab. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
